Previously recorded as MonoSol RX, LLC (to 2018)
34 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
15 more records may belong here and await a decision; they are not counted.
The next term ends in Oct 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
Oct 2027
Next term end
11
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2041 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Jun 2038 · High confidence
Also notable
Ends Sep 2031 · High confidence
Also notable
Ends Jan 2028 · High confidence
Also notable
Ends Nov 2027 · High confidence
Also notable
Ends Oct 2027 · High confidence
Also notable
Ends Jul 2030 · High confidence
System and Method for Making Personalized Individual Unit Doses Containing Pharmaceutical Actives
US 11,806,311
Cited by 20 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
Enhanced Delivery Epinephrine Compositions
US 11,191,737
Cited by 12 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037.
Pharmaceutical Compositions with Enhanced Permeation
US 11,273,131
Granted 2022. Computed term ends 2038.
Method and System for Forming a Pharmaceutical Product Directly onto a Packaging Surface
US 8,936,825
Cited by 59 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
US 7,972,618
The most cited patent in this portfolio, cited by 98 later US patents, top 10% of utility patents granted in 2011 in our data. Protection runs to 2028.
Packaged film dosage unit containing a complexate
US 8,568,777
Cited by 53 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Film Delivery System for Tetrahydrolipstatin
US 8,298,583
Cited by 24 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Stabilized Amine-Containing Actives in Oral Film Compositions
US 9,095,577
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2030.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 4, 2027
- 2 fees due Apr 6, 2027
- 2 fees due May 5 to 7, 2027 · next May 5
- 1 fee due Oct 5, 2027The maintenance fee for Process for Drying a Wet Film with Control of Loss on Drying (US 9,303,918) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Use of Dams to Improve Yield in Film Processing | 23 in force | to Apr 2041 |
| Method and System for Forming a Pharmaceutical Product Directly onto a Packaging Surface | 2 in force | to Sep 2031 |
| Pharmaceutical Compositions with Enhanced Permeation | 1 in force | to Jun 2038 |
| Enhanced Delivery Epinephrine Compositions | 1 in force | to May 2037 |
| Stabilized Amine-Containing Actives in Oral Film Compositions | 1 in force | to Jul 2030 |
| Packaged film dosage unit containing a complexate | 1 in force | to Nov 2027 |
| Film Delivery System for Tetrahydrolipstatin | 1 in force | to Oct 2027 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,298,583 | Film Delivery System for Tetrahydrolipstatin In force · High confidence | In force | High confidence | |
| US 8,568,777 | Packaged film dosage unit containing a complexate In force · High confidence | In force | High confidence | |
| US 7,972,618 | Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent In force · High confidence | In force | High confidence | |
| US 10,034,833 | Sublingual and Buccal Film Compositions In force · High confidence | In force | High confidence | |
| US 10,821,074 | Sublingual and Buccal Film Compositions In force · High confidence | In force | High confidence | |
| US 9,511,033 | Sublingual and Buccal Film Compositions In force · High confidence | In force | High confidence | |
| US 9,095,577 | Stabilized Amine-Containing Actives in Oral Film Compositions In force · High confidence | In force | High confidence | |
| US 10,272,607 | Manufacturing of Small Film Strips In force · High confidence | In force | High confidence | |
| US 10,940,626 | Manufacturing of Small Film Strips In force · High confidence | In force | High confidence | |
| US 9,150,341 | Unit Assembly and Method of Making Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 34: 33 patents ended · 18 applications pending · 28 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.